Last mentioned: Mar 25, 2026
Phase III Initiation
First patient dosed in the pivotal Phase III clinical trial for endometriosis.
Phase III Initiation
First patient dosed at Peking Union Medical College Hospital in China.
Phase III Initiation
First patient dosed at Peking Union Medical College Hospital in China.
Regulatory Designations
FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
Regulatory Designations
HMI-115 receives FDA Fast Track and NMPA Breakthrough Therapy designations.
Trial Expansion
Continued enrollment across global multicenter sites for the 24-week study.
Phase II Data Publication
Results showing efficacy without hormonal side effects published in The Lancet.
Phase II Completion
Global multicenter Phase II trial results published in The Lancet showing efficacy and safety.
Phase II Completion
Positive results from Phase II studies demonstrate pain reduction and safety.
Licensing Agreement
Hope Medicine acquires global rights for HMI-115 from Bayer.
Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies.
Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Hope Medicine has officially initiated its Phase III clinical trial for endometriosis, dosing the first patient with HMI-115. This milestone marks a significant advancement in the development of a first-in-class prolactin receptor antagonist designed to address the high unmet need in women's health.
Hope Medicine has officially initiated its global Phase III clinical trial for HMI-115, a first-in-class monoclonal antibody targeting the prolactin receptor for endometriosis. The dosing of the first patient marks a critical transition toward non-hormonal therapeutic options for a condition affecting nearly 10% of women globally.